




CENTRAL NERVOUS SYSTEM



SUBJECT : Pharmacology

LEC NO. : 7

DONE BY : Batool ALzubaidi

وَقُلْ رَبِّ زِدْنِي عِلْمًا



Antiepileptics

Pharmacology and Toxicology

Central Nervous System Module

Third Year Medical Students

Tareq Saleh

Faculty of Medicine

The Hashemite University

Each convulsion is a seizure but not every seizure is a convulsion

Overview: Epilepsy

• Seizures

Abnormal brain activity, it's effect depends on which area of the brain it occurs, it could be without motor symptoms like absence seizures

- Abnormal excessive neuroactivity in the brain

• Convulsions:

Seizure associated with motor symptoms mostly uncontrolled muscle contractions


- Rapid, repeated muscle contraction and relaxation resulting from excessive neuroactivity in the brain.

• Epilepsy:

Recurrent repeated uncontrolled, unknown etiology

- A neurological disorder of multiple, different seizures resulting from excessive discharge of cerebral neurons.

Single-photon emission coherence tomography (SPECT) can be used to measure regional blood flow in the brain. The image shows an increased blood flow in the left temporal lobe associated with the onset of a seizure in the same area.





Seizures: Etiology

- Trauma Infection of central nervous system

- Encephalitis

- Drugs

- Withdrawal from depressants

- Tumor

Cause could be metabolic » electrolyte imbalance

- High fever Rapid elevation of temperature

- Hypoglycemia

- Extreme acidosis

- Extreme alkalosis


- Hyponatremia

- Hypocalcemia

- Idiopathic

Most cases of epilepsy are idiopathic

Classification of Seizures



Overview: Epilepsy

- **Focal (partial) seizures:**

- Involves one portion of the brain i.e. one lobe.
- Symptoms depend on the site of discharge “primary focus”.
- Possibility of progressing into a generalized tonic-clonic seizure.



Partial seizure

Focal (partial) seizures:

Simple partial

- Confined to a single locus in the brain
- **NO loss of consciousness**
- Single muscle group or a limb

Complex partial

- Consciousness is altered
- Motor dysfunction/hallucination /distortion

Overview: Epilepsy

اللي بيميز ال generalised عن ال partial مش ال motor activity
لانه ال partial ممكن يصير فيها شوية motor activity ببعض
الاحيان حسب المنطقة بالدماغ الي بميزهم عن بعض انه ال
generalised بصير فيها loss of consciousness

• Generalized seizures:

- Starts at a focal point and spreads to involve both hemispheres.
- Could be convulsive or nonconvulsive.
- Associated with immediate loss of consciousness.



Generalized seizure



- Tonic-clonic**
- Loss of consciousness
 - **Tonic** (continuous contractions) and **clonic** (rapid contraction and relaxation)
 - Followed by confusion/exhaustion

Most common type

Seizure is followed by something called postictal (self urination, confusion, loss of memory)

Seizure doesn't have to have motor component

- Clonic**
- Also brief episodes of muscle contraction similar to myoclonic
 - Consciousness is more impaired with clonic

- Absence**
- Brief, abrupt, self-limiting
 - Pediatric: 3-5 until puberty
 - Starring/rapid-eye blinking
 - Characteristic EEG profile



- Tonic**
- Increased muscle tone
 - < 60 seconds

Will lose consciousness

- Atonic**
- Sudden loss of muscle tone "drop attacks"


- Myoclonic**
- Short episodes of muscle contractions i.e., jerks of the limbs

Epilepsy: Therapeutic Strategy

مثلا لو كان السبب brain tumor اكد لو شلناه لازم تنحل المشكلة بس most cases of epilepsy are idiopathic عشانه هيك
احنا ال treatment to manage symptoms to prevent seizures recurrence ال patient seizure free ال يكون انه الهدف

- “No cure”
- Complete suppression of seizures, or
- Decrease the number of episodes with minimal side effects.

How?

- Pharmacological
- Ketogenic diet  For refractory resistant epilepsy that doesn't respond to treatment
- Surgery/Vagal Nerve Stimulation
- Correct the underlying cause



Epilepsy: How to select which drug?

Choice of drug treatment is based on:

- 1- type of seizure
- 2- patient-specific variables (age, comorbidities, lifestyle....)
- 3- characteristics of the drug (cost, adverse effects, interactions...)

في شوية قواعد رئيسية : اولاً لو حدا صار عنده seizure you don't initiate pharmacological treatment, you start to consider using pharmacology
صار more than 2 uncontrolled seizures ليش وحدة ما بنعطي لانها ممكن تكون incidental او السبب metabolic و ما راح ترجع بتقرر تبليش علاج ال epilepsy
لما يصير repeated recurrent seizures .. ثانياً الهدف انه لما يصير single drug with the least dose that can control or prevent seizures later
on ليش لانه معظمهم الهم adverse effects فالهدف تبقي اني استخدم single safest best anti-epileptic drug that can control the condition

Epilepsy: Therapeutic Strategy



نفرض انك اعطيت
 single drug في خيارين
 يا اما ال patient راح
 يصير seizure free او
 ال seizures will
 persist هون شو بتعمل
 you will switch drug و
 تعطي alternative اذا
 زبط بكون ممتاز و اذا
 ما زبط و كان resistant
 بدك تجرب تعمل
 combination و اذا ما
 زبطت بدك تفكر باشياء
 اخرى غير
 pharmacology

How do antiepilepsy medications work?



They should be neurosuppressive

1.
Blocking voltage-gated channels (Na⁺ or Ca⁺⁺)



If the seizures are characterized by just normal firing of neurons you can interfere with action potential propagation » interfering with voltage gated sodium or calcium channels


2.
Enhancing inhibitory GABAergic impulses

3.
Interfering with excitatory glutamate transmission

Antiepileptic drugs

هاي السلايدة متكررة ١٠ مرات بعد كل دوا ف حذفتم عشان
 يقل عدد السلايدات و نفسيا تحسوها صغيرة المحاضرة 🙄

Many anti-epiloptics have multiple mechanisms of actions




MOA:

Blocks voltage-gated Na⁺ channels by binding to inactive state → slow recovery

Phenytoin

لما هدول ال gates يتسكروا يعني ما في
depolarisation يعني ال neuron بضل
على ال resting membrane potential



في البداية يكونوا closed
بس يجي action potential
راح يفتحوا و يصير في sodium influx
خلال ال refractory period
يكونوا inactive لانه
عندهم internal gate
راح تسكروا و ال
phenytoin يرتبط بال
inactive state not the
closed


Phenytoin

MOA:

Blocks voltage-gated Na⁺ channels by binding to inactive state → slow recovery

Indications:

- Focal seizures
- Tonic-clonic
- **NOT** good for absence seizures
- Status epilepticus (after BZD)
- Antiarrhythmic/digoxin toxicity



ما يستخدمهم في ال absence ولا بالاطفال لانه بخلي الوضع اسوء

Second line for epilepsy

مهمة لما تعمل combination

Second line


Pharmacokinetics:

- **Induces CYP2C, CYP3A, UGT**
- “saturable enzyme metabolism”
- **Non-linear** kinetics
- **Toxicity**

ال effect مع ال concentration مش consistent ال effect بتعمل increase in dose شوية

Adverse effects

- Nystagmus, ataxia
- Diplopia, sedation
- **Gingival hyperplasia**
- Peripheral neuropathy/osteoporosis
- **Teratogenic**
- Blood: ↓ folate → Megaloblastic anemia
- **Drug-drug interactions:** e.g., warfarin



Fosphenytoin for IM administration



Carbamazepine

MOA:

Blocks Na⁺ channels

Indications:

- Focal seizures
- Tonic-clonic
- **NOT** good for absence seizures
- Trigeminal neuralgia
- Bipolar disorder Mood enhancement

Has some analgesic effects for neuropathic pain

Pharmacokinetics:

- Absorbed slowly
- Long half-life (~ 30 hours)
- **Induces** CYP2C, CYP3A, UGT

Adverse effects

- Hyponatremia
- Aplastic anemia
- Teratogenic: Spina Bifida
- Drowsiness; headache; dizziness; nausea

Oxcarbazepine

- Prodrug
- Less side effects



Valproic acid

Very important anti-epileptic, broad spectrum used for multiple types of epilepsy

- MOA:**
- Blocks Na⁺ channels
 - Blocks GABA transaminase (GABA-T)
 - Blocks T-type Calcium channels

- Indications:**
- Focal seizures
 - Generalized seizures
 - Absence seizures Preferred option
 - Bipolar disorder

- Pharmacokinetics:**
- **Inhibits** CYP2C9, UGT, epoxide hydroxylase

- Adverse effects**
- Hepatotoxicity
 - Teratogenicity
 - CNS-related

مهم تعرف مين الادوية ال teratogenic

Valproic acid
vs
Sodium valproate
vs
Divalproex sodium

V.I



Lamotrigine

MOA:

- Blocks Na⁺ channels
- Blocks voltage-gated Ca⁺⁺ channels

Indications:

- Focal seizures
- Generalized seizures
- Absence
- Lennox-Gastaut syndrome
- Bipolar disorder

Repetitive therapy
resistant seizures

Adverse effects

- CNS-related side effects
- Severe skin reaction (life-threatening)

Pharmacokinetics:

- Metabolized by UGT
- What will happen when combined with *phenytoin*?
Valproic acid? فكريا فيه



Not first line

Topiramate

MOA:

- Blocks Na⁺ channels
- Blocks L-type Calcium channels
- Carbonic anhydrase inhibitor
- NMDA blocker

Indications:

- Focal seizures
- Generalized seizures
- Migraine prevention

Pharmacokinetics:

- Inhibits CYP2C9

Adverse effects

- Somnolence
- Weight loss
- Paresthesia
- Renal stones
- Oligohidrosis
- hyperthermia

Sedation

Zonisamide

MOA:

- Blocks Na⁺ channels
- Blocks T-type Calcium channels
- Limited carbonic anhydrase inhibitor

Indications:

- Focal seizures

Adverse effects

- CNS adverse effects
- Nephrolithiasis
- Oligohidrosis
- Contraindicated in patients with sulfonamide hypersensitivity

Kidney stones when long term usage

Ethosuximide

MOA:

- Blocks T-type Calcium channels

Indications:

- Absence seizure only
(Drug of choice)

Pharmacokinetics:

- Half-life: 30-60 hrs

Benzodiazepines Phenobarbital

MOA:

- Bind to GABA_A receptors and enhance GABA binding → facilitates Cl⁻ entry → inhibitory

Indications:

- Clonazepam → adjunctive antiseizure therapy
- Diazepam → status epilepticus (**drug of choice**)

I

Gabapentin Pregabalin

MOA:

- Analog of GABA
- It does **NOT** act at GABA receptor
- MOA is unknown

Adverse effects

- Sedation
 - Euphoria
- Risk of abuse

Indications:

- Adjunct therapy for focal seizures
 - Neuropathic pain, e.g., postherpetic neuralgia, diabetic neuropathy
- Preferred with elderly

Pharmacokinetics:

- Secreted unchanged
- Few drug interactions
- Suitable for elderly

Felbamate

MOA:

- Blocks voltage-gated Na⁺ channels
- Blocks NMDA receptors
- Blocks Ca⁺⁺ channels
- Potentiates GABA

Adverse effects

- Aplastic anemia
- Hepatic failure
- Dangerous drug

Indications:

- Reserved for refractory epilepsy
- Lennox-Gastaut syndrome

Pharmacokinetics:

- Inhibits CYP2C19
- Induces CYP3A4

Ezogabine

MOA:

- Open voltage-gated M-type potassium channels → stabilizing resting membrane potential

Adverse effects

- Urinary retention
- QT interval prolongation
- Blue skin discoloration
- Retinal abnormalities

Pharmacokinetics:

- No drug interactions at low doses

V.I

Levetiracetam

MOA:

- unknown

Indications:

- Focal (simple and complex) seizures
- Adjunct therapy for generalized seizures

Adverse effects

- Dizziness
- somnolence



Status Epilepticus


- *Continuous or repetitive seizures (> 20 min) with impaired consciousness during the interictal period.*
- **Management**
 1. **Diazepam** (IV or rectal) → for rapid control.
 2. **Fosphenytoin** (prodrug) or **phenytoin** → long-acting, to maintain control.
 3. **Phenobarbital** → 2nd choice to phenytoin.
 4. **Propofol** (IV anesthesia) → in resistant cases.

Antiepileptics during pregnancy

Using folic acid with epilepsy is a must

- Monotherapy
- The lowest possible dose
- Lamotrigine; gabapentin = safe
- Valproic acid; phenobarbital; phenytoin, others = **contraindicated**
- *Cleft lip, neural tube defect* (patients considering pregnancy while on antiepileptics should receive folic acid supplements)

Gradual withdraws always



V.V.I

AAN Guidelines for Epilepsy Treatment



Level	Recommendation
Level B	LTG use should be considered to decrease seizure frequency.
Levels B and Level C	LTG use should be considered (Level B) and GBP use may be considered (Level C) to decrease seizure frequency in patients aged ≥ 60 years.
Level C	LEV use may be considered to decrease seizure frequency.
Level C	ZNS use may be considered to decrease seizure frequency.
Level C	VGB use appears to be less efficacious than immediate-release carbamazepine (CBZ) use and may not be offered; furthermore, toxicity profile precludes VGB use as first-line therapy.
Level C	PGB use at 150 mg/d is possibly less efficacious than LTG use at 100 mg/d.
Level U	Evidence is insufficient to consider GBP, OXC, or TPM instead of CBZ.
Level U	Evidence is insufficient to consider TPM instead of phenytoin in urgent treatment of new-onset or recurrent focal epilepsy, unclassified generalized tonic-clonic (GTC) seizures, or generalized epilepsy (GE) presenting with GTC seizures.
Level U	Data are lacking to support or refute use of third-generation AEDs, CLB, FBM, or VGB in treating new-onset epilepsy.
Level U	Data are lacking to support or refute use of newer AEDs in treating unclassified GTC seizures.

Recommendation for childhood absence epilepsy

Level	Recommendation
Level B	Unless there are compelling reasons based on adverse events (AEs) profile, ethosuximide (ETS) or VPA use should be considered before LTG use to decrease seizure frequency in treating absence seizures in childhood absence epilepsy.

Figure 12.4 in chapter 12 is
very important

Summary of Therapeutic Strategy

Proper diagnosis

Termination of therapy:

- After 2 years (no fits)
- Gradually

Monotherapy

Start with ***a small dose*** and a **single drug** then gradually increase the dose

Pregnancy:

- Least effective dose of least teratogenic drug
- Folic acid supplements

Consider monitoring of serum drug levels



DRUG	MECHANISM OF ACTION	ADVERSE EFFECTS AND COMMENTS
<i>Carbamazepine</i>	Blocks Na ⁺ channels	Hyponatremia, drowsiness, fatigue, dizziness, and blurred vision. Drug use has also been associated with Stevens-Johnson syndrome. Blood dyscrasias: neutropenia, leukopenia, thrombocytopenia, pancytopenia, and anemias.
<i>Divalproex</i>	Multiple mechanisms of action	Weight gain, easy bruising, nausea, tremor, hair loss, GI upset, liver damage, alopecia, and sedation. Hepatic failure, pancreatitis, and teratogenic effects have been observed. Broad spectrum of antiseizure activity.
<i>Eslicarbazepine acetate</i>	Blocks Na ⁺ channels	Nausea, rash, hyponatremia, headache, sedation, dizziness, vertigo, ataxia, and diplopia.
<i>Ethosuximide</i>	Blocks Ca ²⁺ channels	Drowsiness, hyperactivity, nausea, sedation, GI upset, weight gain, lethargy, SLE, and rash. Blood dyscrasias can occur; periodic CBCs should be done. Abrupt discontinuance of drug may cause seizures.
<i>Ezogabine</i>	Enhances K ⁺ channels	Urinary retention, neuropsychiatric symptoms, dizziness, somnolence, QT prolongation, reports of blue skin discoloration, and retina changes.
<i>Felbamate</i>	Multiple mechanisms of action	Insomnia, dizziness, headache, ataxia, weight gain, and irritability. Aplastic anemia and hepatic failure. Broad spectrum of antiseizure activity. Requires patient to sign informed consent at dispensing.
<i>Gabapentin</i>	Unknown	Mild drowsiness, dizziness, ataxia, weight gain, and diarrhea. Few drug interactions. One hundred percent renal elimination.
<i>Lacosamide</i>	Multiple mechanisms of action	Dizziness, fatigue, and headache. Few drug interactions; Schedule V.
<i>Lamotrigine</i>	Multiple mechanisms of action	Nausea, drowsiness, dizziness, headache, and diplopia. Rash (Stevens-Johnson syndrome—potentially life threatening). Broad spectrum of antiseizure activity.
<i>Levetiracetam</i>	Multiple mechanisms of action	Sedation, dizziness, headache, anorexia, fatigue, infections, and behavioral symptoms. Few drug interactions. Broad spectrum of antiseizure activity.
<i>Oxcarbazepine</i>	Blocks Na ⁺ channels	Nausea, rash, hyponatremia, headache, sedation, dizziness, vertigo, ataxia, and diplopia.
<i>Perampanel</i>	Blocks AMPA glutamate receptors	Serious psychiatric and behavioral reactions, dizziness, somnolence, fatigue, gait disturbance, and falls, long half-life.
<i>Phenytoin</i>	Blocks Na ⁺ channels	Gingival hyperplasia, confusion, slurred speech, double vision, ataxia, sedation, dizziness, and hirsutism. Stevens-Johnson syndrome—potentially life threatening. Not recommended for chronic use. Primary treatment for status epilepticus (<i>fosphenytoin</i>).
<i>Pregabalin</i>	Multiple mechanisms of action	Weight gain, somnolence, dizziness, headache, diplopia, and ataxia. One hundred percent renal elimination.
<i>Rufinamide</i>	Unknown	Shortened QT interval. Multiple drug interactions.
<i>Tiagabine</i>	Blocks GABA uptake	Sedation, weight gain, fatigue, headache, tremor, dizziness, and anorexia. Multiple drug interactions.
<i>Topiramate</i>	Multiple mechanisms of action	Paresthesia, weight loss, nervousness, depression, anorexia, anxiety, tremor, cognitive complaints, headache, and oligohidrosis. Few drug interactions. Broad spectrum of antiseizure activity.
<i>Vigabatrin</i>	Irreversible binding of GABA-T	Vision loss, anemia, somnolence, fatigue, peripheral neuropathy, weight gain. Available only through SHARE pharmacies.
<i>Zonisamide</i>	Multiple mechanisms of action	Nausea, anorexia, ataxia, confusion, difficulty concentrating, sedation, paresthesia, and oligohidrosis. Broad spectrum of antiseizure activity.




ANTIPILEPSY MEDICATION	PROTEIN BINDING*	HALF-LIFE	ACTIVE METABOLITE	MAJOR ORGAN OF ELIMINATION	DRUG INTERACTIONS
<i>Carbamazepine</i>	Moderate	6–15	CBZ-10,11-epoxide	Liver	✓
<i>Eslicarbazepine acetate</i> **^	Low	8–24	Eslicarbazepine (S-lcarbazepine)	Kidney	✓
<i>Ethosuximide</i>	Low	25–26		Liver	✓
<i>Ezogabine</i>	Moderate	7–11	monoacetylated metabolite	Liver	✓
<i>Felbamate</i>	Low	20–23		Kidney/Liver	✓
<i>Fosphenytoin</i> **	High	12–60	phenytoin	Liver	✓
<i>Gabapentin</i>	Low	5–9		Kidney	
<i>Lacosamide</i>	Low	13		Various	
<i>Lamotrigine</i>	Low	25–32		Liver	✓
<i>Levetiracetam</i>	Low	6–8		Hydrolysis	
<i>Oxcarbazepine</i> **	Low	5–13	Monohydroxy metabolite (MHD)	Liver	✓
<i>Phenobarbital</i>	Low	72–124		Liver	✓
<i>Phenytoin</i>	High	12–60		Liver	✓
<i>Primidone</i>	High	72–124	Phenobarbital, PEMA	Liver	✓
<i>Perampanel</i> ^	High	105		Liver	✓
<i>Pregabalin</i>	Low	5–6.5		Kidney	
<i>Rufinamide</i>	Low	6–10		Liver	✓
<i>Tiagabine</i>	High	7–9		Liver	✓
<i>Topiramate</i>	Low	21		Various	✓
<i>Vigabatrin</i>	Low	7.5		Kidney	✓
<i>Valproic Acid (Divalproex)</i>	Moderate/High	6–18	Various	Liver	✓
<i>Zonisamide</i>	Low	63		Liver	✓

Name an AED that is associated with each of the following adverse effects



Sedation

Phenobarbital



Rash

Lamotrigine



Weight gain
or
weight loss

Topiramate



Ataxia

Phenytoin



Hyponatremia

Carbamazepine



Teratogenicity

Valproic acid



Several classes of antiepileptic drugs (AEDs) interfere with the propagation of action potentials in hyperactive epileptic foci by inhibiting the activation of voltage-gated Na⁺ channels. All of the following medications share this mechanism of action, EXCEPT:

- A) Zonisamide
- B) Carbamazepine
- C) Conazepam
- D) Valproic acid
- E) Phenytoin



All of the following mechanisms of action account for the antiepileptic effects of the drug topiramate, EXCEPT:

- a) Voltage-gated Na⁺ channel blockade
- b) L-type Ca⁺⁺ channel blockade
- c) Carbonic anhydrase inhibition
- d) Glutamate NMDA receptor antagonist
- e) Facilitation of Cl⁻ influx at GABA receptor



A 25-year-old woman with generalized epilepsy is well controlled on valproate. She indicates that she is interested in becoming pregnant in the next year. With respect to her antiseizure medication, which of the followings should be considered?

- a) Leave her on her current therapy and start folic acid supplements.
- b) Consider switching to lamotrigine.
- c) Consider adding another antiseizure drug.
- d) Decrease her valproate dose



A 52-year-old man has had several focal seizures with impaired consciousness over the last year. Which is the most appropriate initial therapy for this patient?

- a) Ethosuximide
- b) Levetiracetam
- c) Diazepam
- d) Phenytoin/Carbamazepine combination